Here's How Dry Age-Related Macular Degeneration Market Growing during 2023 - 2032 | Santen Pharmaceuticals Inc., Allergan plc, Bausch Health, Alimera Science Inc, Phio Pharmaceuticals Corp.

Market Overview

Dry Age-Related Macular Degeneration Market Size was valued at USD 8.15 billion in 2021. The dry age-related macular degeneration market industry is projected to grow from USD 8.82 Billion in 2022 to USD 17.92 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.2% during the forecast period (2023 - 2032).

Get Free Sample PDF Brochure:

https://www.marketresearchfuture.com/sample_request/10657

Dry age-related macular degeneration (AMD) presents a significant challenge to global public health, affecting millions of individuals worldwide. Characterized by the progressive deterioration of the macula, a critical area of the retina responsible for central vision, dry AMD leads to vision impairment and, in severe cases, blindness. The aging population, coupled with lifestyle factors such as smoking and poor diet, contributes to the increasing prevalence of this condition. Consequently, the market for dry AMD therapies and interventions is witnessing steady growth, driven by the pressing need for effective treatments and innovative approaches.

Competitive Landscape

The landscape of dry AMD treatment is marked by intense competition among pharmaceutical companies, biotechnology firms, and research institutions striving to develop novel therapies.

Key Companies in the Dry Age-Related Macular Degeneration market include

Santen Pharmaceuticals Inc. (Japan)
Allergan plc (Ireland)
Bausch Health (Canada)
Alimera Science Inc. (US)
Phio Pharmaceuticals Corp (US)
Ocumension Therapeutics Co. Ltd (China)
Belite Bio Inc. (US)
Kubota Vision Inc. (US)
Iveric Bio (US)
Eyestem Research Pvt Ltd (India), among others
These companies invest heavily in research and development to enhance treatment efficacy and expand market presence.

Additionally, smaller biotech firms and startups play a crucial role in driving innovation, leveraging cutting-edge technologies such as gene therapy and stem cell research to explore new treatment modalities. Collaborations and partnerships between industry stakeholders facilitate the exchange of knowledge and resources, accelerating the pace of drug development and clinical trials.

Buy Now Premium Research Report:

https://www.marketresearchfuture.com/checkout?currency=enterprise_user-USD&report_id=10657

Market Segmentation

The global dry AMD market has been divided based on stages, age group, route of administration, diagnosis& treatment, and end user.

The market, based on stages, has been segregated into early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration.

Based on age group,the dry AMDmarket has been divided intoabove 75 years, above 60 years, and above 40 years.

Based on diagnosis & treatment, the dry AMD market has been divided into treatment and diagnosis.Treatment type is further bifurcated into nutrition therapy and telescopic lens implant. Nutrition therapy is again divided into antioxidants and others. Antioxidants arealso segregated as vitamins, zinc, copper, omega-3 fatty acids, and others.

Diagnosis is bifurcated into fluorescein angiogram, preliminary test, optical coherence tomography, and others.

Based on route of administration, the market is bifurcated into oral, intravitreal, and others.

On the basis of end user, the market is bifurcated into hospitals and clinics, diagnostic centers, academic research institutes, and others

Market USP

The unique selling proposition (USP) of the dry AMD market lies in its commitment to addressing the unmet medical needs of patients by offering innovative therapies and personalized treatment approaches. Key factors contributing to the market's USP include:

Advancements in Research and Development: Ongoing research efforts focus on elucidating the underlying mechanisms of AMD pathogenesis and identifying novel therapeutic targets. Innovative technologies such as gene editing and RNA interference hold promise for developing breakthrough treatments.
Patient-Centric Care: Healthcare providers prioritize patient education, early detection, and proactive management strategies to optimize visual outcomes and enhance quality of life. Multidisciplinary care teams comprising ophthalmologists, retinal specialists, and nutritionists collaborate to deliver personalized treatment plans tailored to individual patient needs.
Holistic Approach to Disease Management: Beyond pharmacological interventions, the dry AMD market emphasizes the importance of lifestyle modifications, nutritional supplementation, and regular monitoring to mitigate disease progression and preserve vision. Integrative care models that combine traditional medicine with complementary therapies gain traction, offering patients comprehensive support throughout their treatment journey.
Browse In-depth Market Research Report (171 Pages) on Dry Age-Related Macular Degeneration:

https://www.marketresearchfuture.com/reports/dry-age-related-macular-degeneration-amd-market-10657

Market Regional Insights

The global dry AMD market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominated the global dry age-related macular degeneration market owing to the rising number of patients suffering from the condition. The increasing number of diabetic patients adds to the number of patients suffering from ophthalmologic conditions. The number of patients with retinal diseases such as dry AMD, retinal vein occlusion, and diabetic eye disease is steadily increasing in the US, according to a retrospective study presented during The Association for Research in Vision and Ophthalmology 2020.Europe holds the second largest market share due to the increasing older population and rising patient population. Additionally, improving government initiatives, increasing healthcare frames, and the rising demand for technologically innovative treatmentsaredriving the growth of the dry age-related macular degeneration market in Europe.The Asia-Pacific is the fastest-growing market for age-related macular degeneration as it is developing at a very rapid pace and has shown the emergence of many players. Moreover, the rising prevalence of eye disorders, increasing healthcare spending, and multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. The Rest of the World is expected to witness a restricted growth due to limited access and healthcare affordability among the population. This region is segmented into Middle East, Africa, and Latin America. In the Middle East, the growth of the market is driven by increasing healthcare infrastructure and healthcare expenditure.

Related Reports:

Healthcare Information Systems Market - https://www.marketresearchfuture.com/reports/healthcare-information-systems-market-7325

Remote Patient Monitoring Market - https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905

Pain management Devices Market - https://www.marketresearchfuture.com/reports/pain-management-devices-market-1504

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis regarding diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

This release was published on openPR.